STAT+: Tau in the spotlight at Alzheimer’s conference

STAT PlusBiotech Tau in the spotlight at Alzheimer’s conference You’re reading STAT’s AAIC in 30 newsletter Manage alerts for this article Email this article Share this article By Andrew JosephJuly 12, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. This is the web edition of STAT’s AAIC in 30 newsletter. Sign up to get it in your inbox here. Welcome to the first edition of our pop-up newsletter from AAIC. I’m STAT’s London-based reporter, and I’ll be here with you over the next couple days. I hope those of you in town can find time to escape the abyss of the conference center and enjoy London, because this city in the summer is something special. Maybe you’re ahead of the curve and took in England’s win last night. In which case, maybe you’re joining me in needing to pound the coffee. Any thoughts, questions, or hot takes on Zverev v. Sinner, I’m at [email protected].Advertisement One other note before we get going: STAT has put together a special report on dementia diagnostics, treatments, and care. We also have a special conference discount on offer, so head here and use the code “AAIC” to download the report for only $5. With the exchange rate, that’s less than the cost of this morning’s flat white. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Alzheimer’s, biotechnology, drug development, Pharmaceuticals, Policy, research, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Your guide to the Alzheimer's Association International Conference Recommended The Readout July 10, 2026 STAT Plus: Roche ends Huntington’s gene-silencing programs Biotech July 9, 2026 STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs Advertisement The Readout July 9, 2026 STAT Plus: Prime wins Beam arbitration, clearing path to clinic Adam's Biotech Scorecard July 9, 2026 STAT Plus: 931 days. The drug approval scandal hiding in plain sight Biotech July 9, 2026 STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug Subscriber Picks